HSBC/CALL/MODERNA/250/0.1/15.01.25 | Real-time Boerse Frankfurt Warrants 09:20:48 2024-07-11 am EDT | ||
| 0.184 EUR | +2.79% |
|
| Current month | +31.62% | ||
| 1 month | -64.20% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 24-07-11 | 0.184 | +2.79% |
| 24-07-10 | 0.179 | +11.87% |
| 24-07-09 | 0.16 | +6.67% |
| 24-07-08 | 0.15 | -1.32% |
| 24-07-05 | 0.152 | +5.56% |
Real-time Boerse Frankfurt Warrants
Last update July 11, 2024 at 09:20 am EDT
More quotesStatic data
| Product type | Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | HSBC |
| WKN | HG807L |
| ISIN | DE000HG807L1 |
| Date issued | 2023-02-02 |
| Strike | 250 $ |
| Maturity | 2025-01-15 (188 Days) |
| Parity | 10 : 1 |
| Emission price | 3.46 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.38 € |
|---|---|
| Lowest since issue | 0.054 € |
| Delta | 0.1x |
| Omega | 5.377 |
| Premium | 114.68x |
| Gearing | 55.34x |
| Moneyness | 0.4698 |
| Difference Strike | 132.6 $ |
| Difference Strike % | +53.02% |
| Spread | 0.03 € |
| Spread % | 14.29% |
| Theoretical value | 0.1970 |
| Implied Volatility | 66.18 % |
| Total Loss Probability | 96.15 % |
| Intrinsic value | 0.000000 |
| Present value | 0.1970 |
| Break even | 252.15 € |
| Theta | -0.02x |
| Vega | 0.01x |
| Rho | 0x |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
117.4
USD
Average target price
145.9
USD
Spread / Average Target
+24.19%
- Stock Market
- Warrants
- Warrant
